A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia

American Journal of Cardiology

Volumn 77, Issue 3, 1996, Pages 89A-95A

  Dorian, Paul ^a   Naccarelli, Gerald V ^b   Coumel, Philippe ^c   Hohnloser, Stefan H ^d   Maser, Mary Jane ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM ANTAGONIST; FLECAINIDE; VERAPAMIL;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; VERTIGO;

EID: 0030051443     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89123-0     Document Type: Conference Paper

References (15)

1. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995;332: 162-173.
2. Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988;62(suppl):62D-66D.
3. Wilson TW, Quest DW. Comparative pharmacology of calcium antagonists. Can J Cardiol 1995;11:243-249.
4. Singh BN, Courtney KR. The classification of antiarrhythmic mechanisms of drug action. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia: WB Saunders; 1990:894.
5. Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982;65:348-354.
6. Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, Hawkinson RW, Pritchett ELC, and the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation 1991;83:119-125.
7. Falk RH, Fogel RI. Flecainide. J Cardiovasc Electmphysiol 1994;5:964-981.
8. Wang Z, Pelletier LC, Talajic M, Nattel S. Effect of flecainide and quinidine on human atrial action potentials: role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 1990;82:274.
9. Ikeda N, Singh BN, Davis LD, Hauswirth O. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 1985;5:303-310.
10. Hellestrand DJ, Bexton RS, Nathan AW, Spurrell RAJ, Camm AJ. Acute electrophysiologic effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 1982;48:140-148.
11. Camm AJ, Katitsis D, Nunain SO. Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. Am J Cardiol 1992;70(suppl):33A-37A.
12. Scamps F, Undrovinas A, Vassort G. Inhibition of Ica in single frog cardiac cells by quinidine, flecainide, ethmozine and ethacizin. Am J Physiol 1989;256:C549-C559.
13. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther MI, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
14. Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for Supraventricular arrhythmias. Am J Cardiol 1991;67:976-980.
15. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.